Clinical Trial Update: The ENERGY Study: Evaluation of Safety and Tolerability of INZ-701 in Infants With ENPP1 Deficiency or ABCC6 Deficiency [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update evaluating the safety and tolerability of INZ-701 in infants with ENPP1 or ABCC6 deficiencies.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Abcc6 Deficiency
• Autosomal Recessive Hypophosphatemic Rickets
• Enpp1 Deficiency
• Generalized Arterial Calcification of Infancy
• Pseudoxanthoma Elasticum

Drugs mentioned

• INZ-701

Snippet

Sponsor: Inozyme Pharma | Conditions: Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency, Autosomal Recessive Hypophosphatemic Rickets | Phase 1 | Status: RECRUITING